Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Financing Activities (2016 - 2025)

Protalix BioTherapeutics (PLX) has 14 years of Cash from Financing Activities data on record, last reported at $4.1 million in Q2 2025.

  • For Q2 2025, Cash from Financing Activities changed N/A year-over-year to $4.1 million; the TTM value through Sep 2025 reached $12.8 million, changed N/A, while the annual FY2024 figure was -$16.8 million, 168.09% down from the prior year.
  • Cash from Financing Activities reached $4.1 million in Q2 2025 per PLX's latest filing, down from $5.1 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $42.1 million in Q1 2021 and bottomed at -$26.0 million in Q3 2021.
  • Average Cash from Financing Activities over 5 years is $5.5 million, with a median of $4.1 million recorded in 2022.
  • Peak YoY movement for Cash from Financing Activities: crashed 681.17% in 2021, then soared 200.72% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$4.0 million in 2021, then skyrocketed by 200.72% to $4.1 million in 2022, then soared by 156.02% to $10.4 million in 2023, then plummeted by 65.24% to $3.6 million in 2024, then rose by 13.18% to $4.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $4.1 million in Q2 2025, $5.1 million in Q1 2025, and $3.6 million in Q4 2024.